皇冠官网平台


皇冠登录地址


1. American Depositary Receipt.

The issued ordinary share capital of AstraZeneca PLC is announced at the end of each month via the Regulatory 新闻 Service. The number of ordinary shares represented by ADRs varies over time, with conversion into and out of ADRs.



皇冠登录地址

ADRs are dollar-denominated equity instruments issued in the US markets through a depository bank. They represent ownership of certain equity securities (the 'underlying shares') that are issued and trade in a company's 主页 market(s). Each ADR represents a certain number of underlying ordinary shares, but trading independently of them. 


皇冠登录地址

ADRs are a convenient and cost-effective way to buy shares in international companies.

  • Stocks are quoted in US dollars
  • Dividends are paid in US dollars
  • ADRs trade during normal US trading hours
  • They settle and clear according to US standards
  • No need for custody arrangements outside of US
  • Facilitates price comparisons between securities

皇冠登录地址

AstraZeneca has a level 2 ADR programme which is listed on NYSE under the symbol AZN. The ADR ratio is 1:2, meaning each ordinary share is represented by 2 ADRs. The programme was established in 1999 when Astra and Zeneca merged. Deutsche Bank is depositary bank for the programme.


皇冠登录地址

There are currently over 3,000 ADR programmes of which nearly 1,600 are sponsored. Of these, over 250 are listed on the New York Stock Exchange alongside AstraZeneca including some of the largest companies from Europe, Latin America and Asia Pacific. 


皇冠登录地址

ADRs are bought by both institutional and retail investors. Over $800 billion of ADRs are currently held by institutional holders.


皇冠登录地址

As depositary bank for AstraZeneca, Deutsche Bank undertakes a number of functions including: Issuing and cancelling ADRs; serving as registrar and transfer agent for the ADRs; acting as paying agent, processing dividend payments or other entitlements for the ADR holders; processing corporate actions; and co-ordinating the proxy process for ADR holders.



皇冠官网平台

AstraZeneca’s Form 20-F 资讯rmation in XML format in line with requirements of the US Securities and Exchange Commission (SEC).


皇冠官网平台

AstraZeneca’s financial 资讯rmation for the six months ending 30 June 2019 in XML format in line with requirements of the US Securities and Exchange Commission (SEC).


皇冠官网平台

AstraZeneca’s Form 20-F 资讯rmation in XML format in line with requirements of the US Securities and Exchange Commission (SEC).


皇冠官网平台

AstraZeneca’s financial 资讯rmation for the six months ending 30 June 2018 in XML format in line with requirements of the US Securities and Exchange Commission (SEC).


皇冠官网平台

AstraZeneca’s Form 20-F 资讯rmation in XML format in line with requirements of the US Securities and Exchange Commission (SEC).


皇冠登录地址

ADRs can be bought and sold on the NYSE like any other security. If there is insufficient supply and/or depending on the premium/discount between the price of the ordinary shares and ADRs, ADRs can be created by Deutsche Bank upon receipt of ordinary shares (as shown in the diagram). AstraZeneca’s ADRs also trade in cross-books which match ordinary shareholders looking to create ADRs with ADRs holders looking to cancel and receive ordinary shares - and vice versa. As at 31 December 2019, 510 million ADRs were outstanding with an average of 4 million ADRs traded each day.


皇冠登录地址



(1) Investor 联系s broker and requests purchase of company’s ADR.  If no ADRs are available, the issuance process begins.

(2) Broker 联系s local broker in 主页 market and

(3) the local broker purchases ordinary shares in the 主页 market.

(4) Ordinary shares are deposited with a local custodian and

(5) the custodian instructs the depositary to issue ADRs which represent the shares received.

(6) The depositary issues the ADRs and delivers them in physical form or book form through DTC, Euroclear or Clearstream as applicable.

(7) The broker delivers the DRs to the investor or credits the investor’s account.


皇冠登录地址


New York: +1 212 250 9100  

London: +44 20 7547 6500

Email: adr@db.com

皇冠登录地址

皇冠官网平台

皇冠官网app下载

Thomas Kudsk Larsen

永利皇冠app

Henry Wheeler

Oncology

皇冠官网app下载

Josie Afolabi

BioPharmaceuticals (Respiratory & Immunology)

皇冠官网手机版

Craig Marks

Finance, fixed income

皇冠登录页面

Christer Gruvris

BioPharmaceuticals (CV, Metabolism)

皇冠官网手机版

Tom Waldron

Other medicines

皇冠官网注册

Jennifer Kretzmann

Corporate access, retail investors

皇冠官网注册

Nick Stone

BioPharmaceuticals (Renal), ESG

US general enquiries